Last updated: March 29, 2026
What Is TYBLUME?
TYBLUME (tirbanibulin) is a topical microtubule inhibitor approved by the U.S. Food and Drug Administration (FDA) in December 2020 for the treatment of actinic keratosis (AK), a common precancerous skin condition. Produced by Can-Fite BioPharma, TYBLUME is marketed as a five-day therapy, offering a shorter treatment course compared to competitors.
Current Market Position
TYBLUME targets the actinic keratosis market, estimated at approximately $1.2 billion in the United States in 2022, expected to grow annually by around 4.5% through 2027. Its main competitors include:
- Fluorouracil-based treatments
- Imiquimod creams
- Diclofenac gels
- Ingenol mebutate (sold as Picato, withdrawn in 2020 due to safety concerns)
TYBLUME's five-day topical application distinguishes it from competitors with longer or more complex regimens, potentially enhancing patient adherence and compliance.
Market Adoption and Revenue Generation
As of 2023, TYBLUME's commercialization efforts are limited to the United States under the brand name Erasma. Sales figures remain modest; Can-Fite reported approximately $4 million in revenue from TYBLUME in 2022, with projections aiming toward $15-20 million in the next three years, contingent on increased market penetration.
Key factors influencing market adoption include:
- Prescriber awareness
- Insurance reimbursement policies
- Competitive pricing
- Post-marketing clinical data supporting efficacy and safety
Growth Potential and Expansion Strategies
Geographic Expansion
Plans include regulatory submissions in Europe and Israel, where actinic keratosis diagnoses are rising, and new markets in Asia. These regions present combined markets exceeding $1.5 billion. Regulatory approval timelines are typically 12-24 months, with commercial launches expected within 1-2 years post-approval.
Line Extension Opportunities
Research into chronic skin conditions or different formulations (e.g., gel vs. cream variants) could diversify revenue streams. However, patent protections are primarily secured until 2030, limiting early competition.
Market Challenges
- Competition from established treatments with broader doctor familiarity
- Insurance coverage hurdles limiting access
- Potential safety concerns, although TYBLUME reports few adverse events
Financial Trajectory Outlook
| Year |
Estimated Revenue |
CAGR (from 2022 base) |
Key Assumptions |
| 2023 |
$4 million |
— |
Market awareness, initial reimbursement coverage |
| 2024 |
$7 million |
75% |
Increased physician adoption, expanded payer coverage |
| 2025 |
$12 million |
67% |
Entry into additional markets, clinician education |
| 2026 |
$18 million |
50% |
Broader market penetration, new formulations |
Source: Company projections and industry analysis.
Financial Risks
- Continued competition from other AK treatments
- Pricing pressures due to market dynamics
- Possible delays in regulatory approvals outside the US
- Changes in healthcare reimbursement policies
Key Market Drivers
- Labeling: APproved five-day treatment enhances patient adherence.
- Clinical Data: Ongoing trials showing favorable safety profile.
- Reimbursement: Favorable insurance coverage will accelerate adoption.
- Physician Education: Educational programs to increase awareness.
Regulatory and Reimbursement Landscape
Regulatory approvals in Europe, Israel, and Asia are under review, with potential approvals in 2024-2025. Reimbursement in major markets depends on pricing negotiations, with payers favoring shorter treatment regimens due to lower overall costs.
Competitive Landscape Overview
| Treatment |
Duration |
Market Share (2022) |
Approval Status |
Price Range (per treatment) |
| TYBLUME |
5 days |
N/A (launching) |
FDA approved |
~$450 |
| Fluorouracil creams |
Several weeks |
~30% |
Widely approved |
~$50-$150 |
| Imiquimod creams |
2-16 weeks |
~45% |
Widely approved |
~$325 per pack |
| Diclofenac gel |
2-3 months |
~15% |
Approved |
~$70 |
Conclusions
TYBLUME's short-course treatment offers a competitive edge, especially for patients needing faster resolution of AK lesions. Medical adoption hinges on increased prescriber education and reimbursement access. Geographic expansion within regulatory timelines can diversify revenue streams. Financial growth depends on market penetration momentum and successful navigation of competitive and regulatory challenges.
Key Takeaways
- TYBLUME holds a competitive position with a shorter treatment course.
- Revenue in 2022 was approximately $4 million, with targeted growth toward $15-20 million by 2025.
- Expansion into Europe, Israel, and Asia is planned, with regulatory decisions anticipated over the next 12-24 months.
- Competition remains significant, mainly from fluorouracil and imiquimod therapies.
- Market growth depends on increasing physician awareness and favorable reimbursement policies.
Frequently Asked Questions
1. What distinguishes TYBLUME from existing actinic keratosis treatments?
Its five-day topical regimen contrasts with longer protocols typical of competitors, potentially improving patient compliance.
2. When will TYBLUME be available outside the U.S.?
Regulatory submissions are ongoing, with approval expected in Europe and Israel between 2024 and 2025.
3. How does TYBLUME’s pricing compare to competitors?
It is priced higher than fluorouracil ($50-$150) at approximately $450 per treatment, justified by shorter duration and ease of use.
4. What are the main barriers to market growth?
Limited physician familiarity, insurance reimbursement issues, and competition from well-established treatments.
5. What is the long-term potential for TYBLUME?
Expansion into new markets and line extensions could elevate revenue, but growth relies on clinical data, regulatory success, and payer acceptance.
References
[1] Can-Fite BioPharma. (2022). Annual Report.
[2] Market Research Future. (2022). Global Actinic Keratosis Market.
[3] U.S. Food and Drug Administration. (2020). FDA approval for tirbanibulin (TYBLUME).
